SCHEMBL22441369

SCHEMBL22441369

CCCCC(Cc1cccc(OC)c1)NC(=O)c1ccc2ncccc2c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.50
TAS1R1 Q7RTX1 2/20 0.50
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
ALOX15 P16050 1/20 0.46
HTT P42858 1/20 0.46
PLK1 P53350 1/20 0.46
HPGD P15428 2/20 0.44
POLB P06746 1/20 0.44
RECQL P46063 1/20 0.44
CCR1 P32246 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
PIN1 Q13526 1/20 0.43
PTAFR P25105 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22441365 1.00 TAS1R3 (0.50) TAS1R3TAS1R1RAB9ANPC1ALOX15
SCHEMBL22457745 0.86 TAS1R3 (0.49) TAS1R3TAS1R1RAB9ANPC1ALOX15
SCHEMBL22441336 0.83 TAS1R3 (0.54) TAS1R3TAS1R1HPGDKMT2A
SCHEMBL29368654 0.83 TAS1R3 (0.54) TAS1R3TAS1R1HPGDKMT2A
SCHEMBL22441339 0.83 TAS1R3 (0.54) TAS1R3TAS1R1HPGDKMT2A
SCHEMBL29368864 0.81 TAS1R3 (0.61) TAS1R3TAS1R1RAB9ANPC1HPGD
SCHEMBL22441390 0.81 GRM4 (0.53) TAS1R3TAS1R1RAB9ANPC1HTT
SCHEMBL29368182 0.81 GRM4 (0.53) TAS1R3TAS1R1RAB9ANPC1HTT
SCHEMBL22441388 0.81 GRM4 (0.53) TAS1R3TAS1R1RAB9ANPC1HTT
SCHEMBL22441334 0.81 TAS1R3 (0.55) TAS1R3TAS1R1HPGDALDH1A1PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3931183-B1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE FERRO THERAPEUTICS INC (US) 2025-02-12 EP disclosed
CN-114008024-A Compounds having iron death inducing activity and methods of using the same 费罗治疗公司 2022-02-01 CN disclosed
US-20220002280-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2022-01-06 US disclosed
US-11040964-B2 Compounds and methods of use Ferro Therapeutics, Inc. (US) 2021-06-22 US disclosed
US-20200299283-A1 COMPOUNDS AND METHODS OF USE BRIDGEBIO PHARMA, INC. 2020-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002280-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 TAS1R3 3730/4885TAS1R1 3650/4885RAB9A 2446/4885
US-20200299283-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 TAS1R3 3730/4885TAS1R1 3650/4885RAB9A 2446/4885
US-11040964-B2 Compounds and methods of use AIFM2, GPX4, GPX1 TAS1R3 3730/4885TAS1R1 3650/4885RAB9A 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.